Weekly Supplement: Week Ending March 8, 2024

To download the issue, please CLICK HERE.

Featured in this Weekly Supplement are insights provided by FDA CDER’s David Keire, who has been serving as the Regulatory Chair of the ICH Q2(R2)/Q14 Expert Working Group (EWG), on the just-released analytical procedure development and validation guidelines and how they support the advancing analytical technology. Keire provided the insights at the late-February ICH stakeholder consultation meeting co-sponsored by FDA and Health Canada.

Along with a feature story on a presentation given at a recently held conference by a leading regulator that addresses the challenges and developments in a key area of concern, our Weekly Supplements include a summary listing of the “News in Brief,” drug GMP warning letters and recalls, and EMA non-compliance reports that have been posted on IPQ’s website during the week. Subscribers can then click through to the full posting.

Also provided, where applicable, are links to the parts of in-depth stories and Monthly Updates that have been released during the week.

Appended to the issue is a chronological listing of the headlines of the in-depth stories that IPQ has released since 2020. Readers of the Weekly Supplement are invited to click through to those that are of particular relevance to the regulatory presentation, news briefs, or compliance developments provided in the issue. Those of especially high relevance to the featured regulator story are indicated with a red star.